Research

Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis

Nandini Dendukuri, Karim Khetani, Michelle McIsaac, James Brophy

ABSTRACT

Background: Testing to determine HER2 status has come into focus since the approval of trastuzumab (Herceptin) for the treatment of HER2-positive breast cancer. We compared the cost-effectiveness of various strategies used to test HER2 status, an important first step toward evaluating the overall cost-effectiveness of trastuzumab therapy.

Methods: We performed a systematic review of studies that evaluated concordance between immunohistochemistry and fluorescence in situ hybridization testing to determine HER2 status. We performed a meta-analysis to estimate the distribution of immunohistochemistry scores in each category (0, 1+, 2+, 3+) and the probability of receiving a positive result of fluorescence in situ hybridization (which we assumed to be the “gold-standard” test) for each category. We calculated the accuracy and incremental cost per accurate diagnosis for each testing strategy compared with the base strategy (immunohistochemistry testing, followed by confirmation of 2+ scores by fluorescence in situ hybridization).

Results: The median percentage of patients in each category of immunohistochemistry score was: 0, 36.1%; 1+, 35.5%; 2+, 12.0%; and 3+, 16.2%. The median percentage of results of fluorescence in situ hybridization that were positive in each immunohistochemistry category was: 0, 1.6%; 1+, 4.9%; 2+, 29.8%; and 3+, 92.4%. The base strategy was expected to correctly determine the HER2 status of 96% of patients with breast cancer. Confirmation of the HER2 status by fluorescence in situ hybridization in cases that received a score of 3+ reduced the percentage of false-positive results to 0% and increased the percentage of accurately determined HER2 results to 97.6%. Compared with the base strategy, this strategy was associated with a median incremental cost-effectiveness ratio of $6175 per case of accurately determined HER2 status.

Interpretation: The strategy with the lowest cost-effectiveness ratio involved screening all newly diagnosed cases of breast cancer with immunohistochemistry and confirming scores of 2+ or 3+ with fluorescence in situ hybridization testing.

CMAJ 2007;176(10):1429-34

Overexpression of the human epidermal growth factor receptor-2 (HER2) gene, a breast cancer marker, is associated with rapid tumour growth, increased risk of recurrence after surgery, poor response to conventional chemotherapy and shortened survival. The availability of targeted trastuzumab (Herceptin) therapy for tumours overexpressing HER2 protein (HER2 positive) has brought the need for accurate determination of HER2 status into sharp focus. Trastuzumab therapy improves the survival rate among women with metastatic or localized HER2-positive breast cancer. However, trastuzumab has deleterious side effects and a high cost (Can$50 000 per year); thus, it is important to accurately determine HER2 status. There are 2 tests commonly used to determine HER2 status (Box 1): immunohistochemistry (detects overexpression of HER2 protein) and fluorescence in situ hybridization (detects amplification of the HER2 gene). A widely recommended testing algorithm (referred to here as the base strategy) is to consider an immunohistochemistry score of 3+ as positive, a score of 0 or 1+ as negative, and a score of 2+ as ambiguous and requiring confirmation with fluorescence in situ hybridization. Trastuzumab therapy is currently approved in Canada for use in women with either an immunohistochemistry score of 3+ or a positive fluorescence in situ hybridization result. Studies that showed fluorescence in situ hybridization to be more sensitive than immunohistochemistry in determining HER2 status and a retrospective analysis that showed trastuzumab therapy to be beneficial only in patients who receive a positive result of fluorescence in situ hybridization have raised the issue of whether fluorescence in situ hybridization should be used to determine the HER2 status of all women with breast cancer. In some countries (e.g., Belgium), only patients with a positive result of fluorescence in situ hybridization receive trastuzumab therapy.© 2007 Canadian Medical Association or its licensors

DOI:10.1503/cmaj.061011

See related article page 1443
**Box 1: Description of immunohistochemistry and fluorescence in situ hybridization tests to determine HER2 status**

**Immunohistochemistry**
- Polyclonal or monoclonal antibodies recognize and bind to HER2 protein in the tissue section, which allows the tester to visualize the location and relative amount of HER2 protein
- Semiquantitative scoring system
  - 0: no circumferential membrane staining (negative)
  - 1+: partial staining in more than 10% of cells (negative)
  - 2+: thin circumferential staining in more than 10% of cells (ambiguous)
  - 3+: intense thick circumferential membrane staining (positive)

**Fluorescence in situ hybridization**
- Fluorescent-labelled probes recognize and bind to the HER2 gene in cell nuclei, which allows the tester to visualize and count the copies of HER2 per cell
- Result is positive for HER2 amplification if the ratio of HER2 signals to chromosome 17 centromeres is greater than 2

Immunohistochemistry is easier to perform than fluorescence in situ hybridization and is substantially less expensive (about 20% of the cost). Immunohistochemistry can be performed in most surgical pathology laboratories. Fluorescence in situ hybridization, on the other hand, is performed only at select sites because specialized equipment and training are required. Despite these arguments in favour of immunohistochemistry testing, there are concerns that it is less accurate, is not standardized and has poor reliability; however, reliability has been improved by the availability of commercial kits. Fluorescence in situ hybridization has generally been shown to have better validity and reliability and is widely considered to be the “gold standard.”

We estimated the incremental cost-effectiveness of various strategies used to determine HER2 status (based on immunohistochemistry and fluorescence in situ hybridization). This analysis is a necessary precursor to a full cost-effectiveness analysis of trastuzumab therapy for different stages of breast cancer.

**Methods**

We performed a search of the PUBMED, EMBASE and MEDLINE databases to identify relevant studies published before June 2006. We used the following keywords: (sensitivity OR specificity OR reliability OR reproducibility OR validity OR interobserver OR intraobserver OR accuracy OR predictive value) AND IHC (or immunohistochemistry) AND FISH (or fluorescence in situ hybridization) AND HER2 AND breast. We included studies that met the following criteria: published in English or French in a peer-reviewed journal; included human patients; included consecutive patients or a random sample; reported agreement between results of immunohistochemistry and fluorescence in situ hybridization using standard cutoff scores; and used assays (following manufacturers instructions) licensed by Health Canada to identify patients eligible for trastuzumab therapy. We also searched the bibliographies of the included articles to identify additional relevant studies.

Some of the included studies had a nonrepresentative patient sample, despite including consecutive patients, because patients were recruited at centres where they had been referred for fluorescence in situ hybridization testing, which resulted in an overrepresentation of cases with 2+ or 3+ immunohistochemistry scores. This selection bias (commonly referred to as verification bias) could artificially increase the sensitivity of immunohistochemistry but decrease its specificity. In some studies the presence of the bias was apparent from the methods. If the percentage of cases with scores of 2+ or 3+ exceeded 40%, we treated the study as having selection bias, even if this bias was not evident from the methods. We did not include these studies while estimating the distribution of immunohistochemistry scores, but we did include them while estimating the rate of positive results of fluorescence in situ hybridization.

We performed a Bayesian meta-analysis to estimate the distribution of immunohistochemistry scores (0, 1+, 2+, 3+) and the probability of obtaining a positive result of fluorescence in situ hybridization for each category of immunohistochemistry score. We analyzed the results of the 0 and 1+ categories separately where possible. We expected the lowest rate of positive fluorescence in situ hybridization results to occur in the immunohistochemistry 0 category and the highest rate to occur in the 3+ category. The goal of this analysis was to estimate the percentage of patients whose HER2 status had been accurately determined by immunohistochemistry. We repeated the analysis using the subset of studies that reported results of immunohistochemistry and fluorescence in situ hybridization performed at the same site. This eliminated the studies with high variability in the immunohistochemistry assay that could have been caused by the test being performed at multiple laboratories. We also excluded studies from this repeat analysis if we could not determine whether all immunohistochemistry tests had been carried out using a licensed assay.

Under the Bayesian approach, prior knowledge, summarizing our uncertainty about the unknown parameters, is combined with information in the observed data (via the likelihood) to yield a posterior distribution for the unknown parameters. Descriptive statistics for the unknown parameters, such as the median and 95% credible interval (Bayesian equivalent of a confidence interval), can be determined from the posterior distribution. We selected prior distributions to allow all parameter possibilities to have equal weight so that the observed data would dominate the final result. The analysis was implemented using the WinBUGS software program (version 1.4).

We performed cost-effectiveness analyses of 7 diagnostic strategies (Table 1) from the perspective of the Ministry of Health and Social Services in Quebec. We compared the dif-
different strategies based on the combination of immunohistochemistry and fluorescence in situ hybridization tests performed to determine HER2 status. The costs of testing and treatment were obtained from billing information maintained by the provincial health insurance agency in Quebec. The probability of an accurate determination of HER2 status based on each strategy was estimated using the posterior distributions obtained by meta-analysis.

All strategies were compared with the “base strategy,” which involves screening all patients who received a new diagnosis of invasive breast cancer with immunohistochemistry followed by confirmatory testing of 2+ scores with fluorescence in situ hybridization. Any strategy that was more expensive but less accurate than another strategy (i.e., not economically attractive) was considered to be “dominated” and was removed from the analysis. Strategies that were less effective and less expensive were also eliminated, because they were unlikely to be acceptable to lower the number of women whose HER2-positive status is accurately diagnosed. We compared the remaining strategies with the base strategy using an incremental cost-effectiveness ratio (defined as the ratio of the difference in costs to the difference in the number of cases with accurately determined HER2 status). We must emphasize that the incremental cost-effectiveness ratio reported here refers only to the cost per diagnosis, not to the cost of trastuzumab therapy. Any strategy that was less accurate but had a higher incremental cost-effectiveness ratio than another strategy was also considered dominated by “extended dominance” (i.e., less attractive in terms of cost per additional accurate diagnosis).

We assessed the robustness of our cost-effectiveness analysis by varying all input variables simultaneously over plausible ranges. The purpose of the sensitivity analysis was to estimate the confidence interval around the incremental cost-effectiveness ratios when allowing for uncertainty in all the variables in our model. The distributions of the immunohistochemistry scores and the rate of positive results of fluorescence in situ hybridization were determined from the meta-analysis. For the distribution of the cost of each test, we used a uniform distribution over the interval defined by +/-20% around the cost.

Results

The study selection process is summarized in Fig. 1. The results from the 17 included studies11,13,14,19,20,22–33 are presented in Table 2. Six studies were identified as having selection bias.11,19,20,25,32,33 Sixteen of the included studies used the Dako HercepTest for immunohistochemistry; the remaining study used Ventana Medical Systems’ Pathway assay.30 All of the included studies used the PathVision kit from Vysis for fluorescence in situ hybridization.

The results of the Bayesian meta-analysis are summarized in Table 3. We obtained similar results in the subgroup analysis of 15 studies in which the immunohistochemistry and fluorescence in situ hybridization were performed at the same site (data not shown).11,13,14,22–33 The number of breast cancer cases in the immunohistochemistry 0 and 1+ categories accounted for about 70% of all cases, about 50% of whom had an immunohistochemistry score of 1+. The rate of positive results of fluorescence in situ hybridization was very low (me-
median $164 000, or about 6–23 false-positive results per 1000 breast cancer patients screened. Based on these estimates, the median number of positive results of fluorescence in situ hybridization per 1000 breast cancer patients screened was 211 (95% credible interval 162–268). The estimated percentages of true- and false-positive results that would be expected using each testing strategy are presented in Appendix 1 (available online at www.cmaj.ca/cgi/content/full/176/10/1429/DC1). The results of the cost-effectiveness analysis are shown in Appendix 2 (available online at www.cmaj.ca/cgi/content/full/176/10/1429/DC1) and are presented in terms of costs per 1000 breast cancer cases screened (Canadian dollars, 2006 equivalent). The current cost of immunohistochemistry is $108 per test, and the current cost of fluorescence in situ hybridization is $467 per test (includes both technical costs [e.g., reagents and equipment] and cost of the pathologist’s time). Under the base strategy (Strategy 1), the median cost of testing per 1000 women was estimated to be $164 000, and the median percentage of accurately identified cases was estimated to be 96%. Of the remaining strategies, 3 were not dominated or eliminated because of lower effectiveness than other studies: strategy 5 (fluorescence in situ hybridization testing in cases with an immunohistochemistry score of 2+ or 3+), strategy 6 (fluorescence in situ hybridization testing in cases with an immunohistochemistry score of 1+, 2+ or 3+) and strategy 7 (fluorescence in situ hybridization for all breast cancer cases). The median incremental cost-effectiveness ratios for these strategies were between $6175 (strategy 5) and $8401 (strategy 7) per accurately determined HER2 status. The increase of 1.6% in the median percentage of accurate diagnoses with strategy 5 compared with the base strategy was due to the reduction of false-positive results to 0%. Thus, strategy 5 would reduce the cost of trastuzumab therapy by about $0.6 million per 1000 women screened. Strategies 6 and 7 were much more expensive because they involved testing the large group of patients who received an immunohistochemistry score of 0 or 1+, among whom the rate of positive results of is low. Strategy 7 had the highest median cost but also had a 4.4% increase in the number of accurate diagnoses compared with the base strategy. This was expected because we considered fluorescence in situ hybridization to be the gold standard. The sensitivity analysis allowed us to determine the 95% confidence intervals for the incremental cost-effectiveness ratios (cost per accurate diagnosis) of the 3 competing strate-

### Table 2: Summary of studies included in the meta-analysis and cost-effectiveness analysis of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to determine HER2 status

| Study                  | No. of patients | IHC score; % of patients | IHC score; % of patients with positive FISH result |
|------------------------|-----------------|--------------------------|-----------------------------------------------|
| **Reported combined results for IHC 0 and 1+ scores** |                 |                          |                                              |
| Hoang et al,24 2000    | 100             | 74.0                     | 2.0                                           |
| Kakar et al,30 2000    | 112             | 70.5                     | 15.2                                          |
| Bartlett et al,13 2001 | 210             | 85.2                     | 10.0                                          |
| Lebeau et al,24 2001   | 78              | 56.4                     | 20.5                                          |
| Press et al,14 2002    | 117             | 74.4                     | 11.1                                          |
| Dowsettl et al,23 2003 | 426             | 63.4                     | 12.7                                          |
| Mrozowski et al,13 2004* | 360         | 2.8                      | 87.5                                          |
| Yaziji et al,11 2004*  | 2913            | 49.0                     | 39.5                                          |
| Lottner et al,27 2005  | 215             | 78.1                     | 11.6                                          |
| Loring et al,26 2005   | 110             | 56.4                     | 15.5                                          |
| **Reported separate results for IHC 0 and 1+ scores** |                 |                          |                                              |
| Tsuda et al,28 2001    | 101             | 41.6                     | 34.7                                          |
| McCormick et al,32 2002* | 198        | 26.8                     | 29.8                                          |
| Roche et al,19 2002†   | 119             | 7.6                      | 8.4                                           |
| Ogura et al,23 2003    | 110             | 24.6                     | 47.3                                          |
| Lal et al,31 2004      | 2279            | 44.6                     | 31.4                                          |
| Dolan et al,25 2005    | 129             | 1.6                      | 16.3                                          |
| Press et al,20 2005†   | 842             | 36.5                     | 17.8                                          |

*Distribution of sample test scores was not representative of the population.
†Immunohistochemistry was performed at various laboratories, and fluorescence in situ hybridization was performed at a central facility.
gies: strategy 5, $3351–$12 230; strategy 6, $3913–$13 630; strategy 7, $5315–$13 260.

Interpretation

The availability of an efficacious, yet expensive, treatment for HER2-positive breast cancer underlines the need for accurate determination of HER2 status. We performed a systematic review and cost-effectiveness analysis that compared various testing strategies involving 2 widely used tests to determine HER2 status.

Based on our meta-analysis, we estimated that, for every 1000 breast cancer patients whose HER2 status was tested by immunohistochemistry, 362 would receive a score of 0, 355 would receive a score of 1+, 120 would receive a score of 2+, and 162 would receive a score of 3+. We estimated that the number of true HER2-positive cases would be 211. Among the cases that received an immunohistochemistry score of 3+, the rate of false-positive results could be as high as 7.6%. For every 1000 women screened, about 12 would receive a false-positive result and would be exposed to the risks of trastuzumab therapy with virtually no chance of gaining the benefits of this treatment. If the HER2 status of these women were accurately determined, the cost of trastuzumab therapy would be reduced by about $0.6 million per year. About 20 000 women receive a diagnosis of breast cancer every year in Canada. Of these women, an estimated 4218 would truly be HER2 positive and about 240 would receive a false-positive result of fluorescence in situ hybridization (FISH). If the HER2 status of these women was accurately determined, the cost of trastuzumab therapy would be reduced by about $12 million across the country each year.

Although fluorescence in situ hybridization is less than 100% sensitive and specific, the literature suggests that it is superior to immunohistochemistry. Therefore, we considered it a reasonable assumption to view fluorescence in situ hybridization as the gold standard. A widely followed practice is to screen all cases of breast cancer with the use of immunohistochemistry and to perform fluorescence in situ hybridization to confirm the result only if the score is 2+. However, it is of interest to evaluate the benefit of fluorescence in situ hybridization testing in cases with scores other than 2+. We found the incremental cost-effectiveness ratio was lowest when cases with immunohistochemistry 2+ and 3+ scores were confirmed by fluorescence in situ hybridization. If all women with newly diagnosed breast cancer were screened with fluorescence in situ hybridization, the cost of testing would be increased by about $303 000 for every 1000 women screened (compared with Strategy 1); however, the percentage of accurate diagnoses would be expected to be 100%.

In previous cost-effectiveness analysis, Elkin and colleagues reached similar conclusions, although their model included only women with metastatic breast cancer and their analyses adjusted for the efficacy of trastuzumab. We believe that the costs of testing obtained from the Ministry of Health and Social Services in Quebec reflect of the relative costs of immunohistochemistry and fluorescence in situ hybridization testing; thus, our conclusions should be generalizable beyond the province of Quebec.

Besides cost-effectiveness, there are other reasons to be cautious about performing confirmatory testing and prescribing trastuzumab therapy to women who receive an immunohistochemistry score of 1+. In particular, the ramifications of not prescribing trastuzumab therapy in these cases are unknown; cases with 0 and 1+ scores were not included in the HER2 clinical trials. One study showed there is no significant difference in survival (in the absence of treatment) among women with an immunohistochemistry score of 0 or 1+. Patients with such scores who receive a positive result of fluorescence in situ hybridization generally have been found to have a low level of HER2 amplification. To date, there is no literature on the relation between trastuzumab efficacy and level of HER2 amplification. Thus, there is no evidence that trastuzumab therapy is beneficial to patients who have an immunohistochemistry score of 0 or 1+. It is therefore hard to justify the increased costs of further testing (by fluorescence in situ hybridization) in this group of patients; this would substantially impact the volume of testing, which would potentially increase the need to purchase more equipment and further increase costs.

Although our analysis has helped to identify a testing strategy with the lowest incremental cost-effectiveness ratio, a major limitation is that our study was cross-sectional and did not account for the longitudinal costs and benefits of trastuzumab treatment. A more complete analysis would ac-

| IHC category | % of patients, median (95% credible interval)* | Expected no. per 1000 breast cancer patients screened, median (95% credible interval) | % of patients, median (95% credible interval) | Expected no. per 1000 breast cancer patients screened, median (95% credible interval) |
|--------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| 0            | 36.1 (4.4–64.2)                             | 362 (44–642)                               | 1.6 (0.9–2.8)                              | 6 (1–13)                                   |
| 1+           | 35.5 (7.4–67.4)                             | 355 (74–674)                               | 4.9 (2.6–17.9)                             | 18 (8–30)                                  |
| 2+           | 12.0 (3.5–21.4)                             | 120 (35–214)                               | 29.8 (12.0–56.5)                           | 34 (8–85)                                  |
| 3+           | 16.2 (10.7–22.9)                            | 162 (107–230)                              | 92.4 (87.1–96.2)                           | 149 (99–212)                               |

*May not add up to 100% owing to rounding.
count for the efficacy of trastuzumab, the increased life expectancy (based on cancer stage and patient age), the increased risk of cardiac toxicity with trastuzumab therapy and the cost to patients who receive a false-negative result and do not receive treatment. This is a necessary first step toward such an analysis.

In conclusion, we have shown that the strategy with the lowest cost-effectiveness ratio for HER2 testing, compared with current practice, is to screen all breast cancer patients with immunohistochemistry and to confirm 2+ and 3+ scores with fluorescence in situ hybridization. In addition to improving specificity, this approach could lead to major cost savings in treatment with trastuzumab.

This article has been peer reviewed.

From the Technology Assessment Unit (Dendukuri, Melsaac, Brophy) and the Department of Pathology (Khetani), McGill University Health Centre; and the Departments of Epidemiology and Biostatistics (Dendukuri) and Medicine (Brophy), McGill University, Montréal, Que.

Competing interests: None declared.

Contributors: Nandini Dendukuri and James Brophy contributed to the conception and design of the study. Nandini Dendukuri and Karim Khetani contributed to the data acquisition. Nandini Dendukuri, Michelle Melsaac and James Brophy contributed to the data analysis. All of the authors contributed to the interpretation of data, revised the article for important intellectual content and approved the final version for publication.

Acknowledgement: Nandini Dendukuri and James Brophy are recipients of career awards from le Fonds de la recherche en santé du Québec.

REFERENCES
1. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998;16:43-28.
2. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
3. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2839-48.
4. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al.; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:159-72.
6. Rosonod EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
7. Ellkin EB, Weinstein MC, Winer EP, et al. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 2004;22:954-61.
8. Neut MJ, Albrecht IA, Clarysse B, et al. Cost-effectiveness of Herceptin: a standard cost model for breast-cancer treatment in a Belgian university hospital. Int J Technol Assess Health Care 2005;21:122-7.
9. Nornum J, Rispens T, Olsen JA. A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis. Ann Oncol 2005;16:909-14.
10. Hicks DG, Tubbs RR. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Hum Pathol 2005;36:250-61.
11. Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 2004;291:1973-7.
12. Bilous M, Dowski M, Hanau W, et al. Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol 2003;16:173-82.
13. Bartlett JM, Going JJ, Mallon EA, et al. Evaluating HER2 amplification and overexpression in breast cancer. J Pathol 2001;195:422-8.
14. Press MF, Slamovits D, Flick EE, et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. Clin Oncol 2002;20:1095-105.
15. Mass RD, Press MF, Anderson S, et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 2005;6:38-40.
16. Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunohisto- type and gene amplification. J Clin Oncol 2001;19:2587-95.
17. Bartlett J, Mallon E, Cooke T. The clinical evaluation of HER-2 status: Which test to use? J Pathol 2003;199:411-7.
18. Begg CB, Greenes Robert. Assessment of diagnostic tests when disease verification is subject to selection bias. Biometrics 1983;39:207-15.
19. Köcher PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Clin Oncol 2001;19:3534-41.
20. Press MF, Saunter G, Bernstein L, et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 2005;11:6589-607.
21. Gelman A, Karlin I, Stern H, et al. Bayesian data analysis. Boca Raton (FL): Chapman & Hall; 2003.
22. Loo L, Deininger DL, Kalte C, et al. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 2001;19:334-43.
23. Dowsett M, Bartlett J, Ellis IO, et al. Comparison between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 Centres. J Pathol 2003;199:418-23.
24. Hoang MP, Sahin AA, Ordonez NG, et al. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol 2000;113:852-9.
25. Dolan M, Snover D. Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice. Am J Pathol 2005;166:788-90.
26. Loring F, Cammins R, O’Grady A, et al. HER-2 positivity in breast carcinoma: a comparison of chromogenic in situ hybridization with fluorescence in situ hybridization in tissue microarrays, with targeted evaluation of intratumoral heterogeneity by in situ hybridization. Appl Immunohistochem Mol Morphol 2005;13:194-200.
27. Lottner C, Schwarz S, Diermeier S, et al. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer. J Pathol 2005;205:577-84.
28. Tsuda H, Akiyama F, Terasaki H, et al. Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER2 overexpression. Cancer 2001;91:1295-74.
29. Ogura H, Akiyama F, Kasumi F, et al. Evaluation of HER-2 status in breast carcinomas by fluorescence in situ hybridization and immunohistochemistry. Breast Cancer Res Treat 2003;82:334-40.
30. Kakar S, Pangasovana N, Stevens JM, et al. HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival. Mol Diagn 2000;5:199-207.
31. Li L, Salazar PA, Hudis CA, et al. HER-2 testing in breast cancer using immuno- histochimical analysis and fluorescence in situ hybridization: a single-institution experience of 2279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol 2004;121:591-6.
32. McCormick SR, Lilemore TL, Benke E, et al. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays. Am J Clin Pathol 2002;117:935-43.
33. Mrozowicki AK, Olszewski WP, Piascik A, et al. HER2 status in breast cancer determined by IHC and FISH: comparison of the results. Pol J Pathol 2004;55:65-71.
34. Ministère de la santé et des services sociaux du Québec. Centre d’activités laboratoires de biologie médicale: Mesure de la production des laboratoires. Annexe B: Liste des procédures de laboratoires par sous-sections 2006–2007. Available: http://mssaq.msss.gouv.qc.ca/DrE conform/AnnexeB.pdf (accessed 2007 Apr 12).
35. Paulletti G, Dandeker S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000;18:3561-4.

Correspondence to: Dr. Nandini Dendukuri, Rm. R4.09, McGill University Health Centre, 689 Pine Ave. W, Montréal QC H3A 1A1; fax 514 843-1493; nandini.dendukuri@mcgill.ca